John M. Richart

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Elizabeth I. Buchbinder, Janice P. Dutcher, Gregory A. Daniels et al. · Journal for ImmunoTherapy of Cancer · 2019 · 147 citations · Full text

Medicine, Immunology, Oncology +14

Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT

Zachariah DeFilipp, Rafael F. Duarte, John A. Snowden et al. · Biology of Blood and Marrow Transplantation · 2016 · 64 citations · Full text

Medicine, Hematology, Preventive Medicine +14

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica Perritt et al. · Journal for ImmunoTherapy of Cancer · 2016 · 43 citations · Full text

Life Sciences, Immunology, Oncology +14

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

Joseph I. Clark, Michael K. Wong, Howard L. Kaufman et al. · Clinical Genitourinary Cancer · 2016 · 34 citations · Full text

Medicine, Immunology, Oncology +15

Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosis

Adrian M. Di Bisceglie, John M. Richart · Liver International · 2006 · 31 citations

Medicine, Pathology, Surgery +17